Edwards Lifesciences (NYSE:EW) Raised to Buy at Wall Street Zen

Edwards Lifesciences (NYSE:EW) was upgraded by Wall Street Zen from a “hold” rating to a “buy” rating in a note issued to investors on Saturday, Wall Street Zen reports.

Several other research analysts have also recently issued reports on EW. Leerink Partners raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and upped their price target for the company from $87.00 to $101.00 in a report on Friday, July 24th. Mizuho raised their price objective on Edwards Lifesciences from $100.00 to $105.00 and gave the stock an “outperform” rating in a research note on Wednesday, July 15th. Citigroup lifted their target price on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. BTIG Research reaffirmed a “buy” rating and set a $110.00 target price on shares of Edwards Lifesciences in a research report on Friday. Finally, TD Cowen reaffirmed a “buy” rating on shares of Edwards Lifesciences in a report on Tuesday, July 21st. Seventeen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $100.27.

Edwards Lifesciences Price Performance

Shares of Edwards Lifesciences stock opened at $84.54 on Friday. Edwards Lifesciences has a 52 week low of $72.30 and a 52 week high of $96.29. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. The stock has a market cap of $48.68 billion, a PE ratio of 48.59, a price-to-earnings-growth ratio of 2.21 and a beta of 0.85. The company’s 50-day moving average price is $89.16 and its two-hundred day moving average price is $85.81.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The company had revenue of $1.74 billion during the quarter, compared to analyst estimates of $1.70 billion. During the same quarter last year, the firm posted $0.67 EPS. The business’s revenue for the quarter was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, sell-side analysts anticipate that Edwards Lifesciences will post 3 EPS for the current fiscal year.

Insider Activity

In related news, VP Annette Brüls sold 2,644 shares of the company’s stock in a transaction on Friday, August 28th. The stock was sold at an average price of $89.98, for a total transaction of $237,907.12. Following the transaction, the vice president directly owned 17,984 shares of the company’s stock, valued at approximately $1,618,200.32. The trade was a 12.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Daniel Lippis sold 619 shares of the stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the completion of the sale, the vice president directly owned 40,034 shares of the company’s stock, valued at approximately $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 5,664 shares of company stock worth $511,918. 0.31% of the stock is owned by corporate insiders.

Institutional Trading of Edwards Lifesciences

Several institutional investors have recently made changes to their positions in EW. California State Teachers Retirement System lifted its position in Edwards Lifesciences by 9,187.8% in the 2nd quarter. California State Teachers Retirement System now owns 80,962,062 shares of the medical research company’s stock worth $7,323,828,000 after buying an additional 80,090,362 shares in the last quarter. BlackRock Inc. purchased a new position in shares of Edwards Lifesciences during the 2nd quarter valued at $5,318,092,000. Bank of New York Mellon Corp acquired a new position in shares of Edwards Lifesciences in the second quarter worth $1,274,082,000. Norges Bank acquired a new position in shares of Edwards Lifesciences in the fourth quarter worth $803,686,000. Finally, Bank of America Corp DE purchased a new stake in shares of Edwards Lifesciences during the second quarter worth $605,397,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Key Edwards Lifesciences News

Here are the key news stories impacting Edwards Lifesciences this week:

• Positive Sentiment: CMS expands TAVR coverage: The Centers for Medicare and Medicaid Services will extend Medicare coverage to certain patients with severe aortic stenosis who do not yet have symptoms. The broader eligible patient population could increase demand for Edwards’ TAVR valves and procedures, a particularly important growth opportunity for the company. CMS expands TAVR Medicare coverage to asymptomatic patients
• Positive Sentiment: Company welcomes the policy: Edwards said the national coverage determination should improve patient access to TAVR while reinforcing the role of multidisciplinary Heart Teams. The company also reaffirmed its 2026 financial guidance following the decision, suggesting no immediate deterioration in its outlook. Edwards Lifesciences Reaffirms 2026 Guidance Following Medicare TAVR Decision
• Positive Sentiment: Analysts remain bullish: Citi initiated or reiterated a Buy view, while BTIG reaffirmed its Buy rating with a $110 price target. William Blair also maintained a Buy rating, citing the expanded TAVR coverage and inclusion of asymptomatic patients. These targets imply substantial potential upside from recent trading levels. Analyst Buy Rating on Edwards Lifesciences
• Neutral Sentiment: Why the stock may still be under pressure: The reports identify no new company-specific negative catalyst. Investors may be waiting for evidence that the CMS change translates into procedure volumes and revenue, while Edwards’ relatively elevated valuation—about 49 times earnings—could make the shares sensitive to profit-taking or broader market weakness.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease. Its products are designed to treat conditions affecting the heart valves and related cardiovascular structures, helping patients with diseases such as aortic stenosis, mitral regurgitation and tricuspid valve disorders.

The company’s portfolio includes transcatheter aortic valve replacement systems, including its SAPIEN platform, as well as transcatheter mitral and tricuspid therapies and surgical heart valve products.